Hi all
Thought this 14 minute interview on 27 April 2017 may be a good outline of how MSCs work and summary of the recent progress made with our phase 3 programs.
brief notes:
-Potential CHF breakthrough or RAT designation after NIH read out end of this year
-Talks about Japan aGVHD & Phase 3 trial in US, read out end of 2017/early 2018
-Disc program; single administration shows durable effects
-MNK hospital based w $3bn in revenue, committed to regenerative medicine. MNK need to diversify their revenue, so far interaction is positive.
-RA; Interviewer believes this is game-changing data.
- Financing: Non-dilutive funding mentioned.
Cell & Gene Interview Apr 27 2017
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71720 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 10463 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |